• Imagin Medical Inc. is a surgical imaging company building a platform of technological products designed to improve endoscopic surgeries through adaptable equipment that makes it easier to see anomalies such as cancerous tumors
• The company’s initial product launch will focus on bladder cancers visible under blue light thanks to a dye on the market that currently depends on the acquisition of expensive new equipment by hospitals
• Imagin’s proprietary i/Blue Imaging (TM) System resolves some of the expense and flexibility concerns expressed by urologists, which will grant surgeons the capacity to better root out cancers
• Imagin has announced an offering of up to $3 million in aggregate principal in convertible notes, and closed the initial $750,000 tranche last month

Science fiction introduced the world to the concept of the invisible man — a person who could move through society without anyone knowing where he was. Imagin Medical (CSE: IME) (OTCQB: IMEXF) has improved on the trope of science fiction, making it possible to better see the “invisible” interior recesses of men and women during medical procedures so that surgeons can more effectively root out cancers in a minimally invasive manner. Imagin Medical will launch its platform with the introduction of the i/Blue Imaging (TM) System, a proprietary imaging technology based on advanced optics and light sensors. The value of Imagin’s platform is that it makes surgery-revolutionizing technology more available to hospitals by providing it in manner adaptable to the equipment hospitals already own. “One very good technology that has been developed is what’s known as blue light cystoscopy,” Kaiser Permanente urologist Mehrdad Alemozaffar explains in an Imagin webinar on the company’s technology (https://ibn.fm/Y9Qu2). “Cysview is the drug that’s used,” Alemozaffar states. “What’s done with blue light cystoscopy is that the drug is instilled into the bladder just before the patient goes to the operating room and in the operating room a camera … emits a blue light and, essentially, any cancer would have taken up that drug much more rapidly, and under this blue light actually shines back at us a very bright pink color.” The pink definition of the tumor allows surgeons to see the cancer better than if they were looking at it under standard white light. The company’s webinar states that the blue light procedure helps identify 25 percent more tumors but that it is used in less than 10 percent of urological procedures, despite its recommendation by the American Urological Association, in part due to the prohibitive costs of the equipment involved as well as the challenges of switching back and forth between white and blue light systems during the course of the procedure. Imagin’s tech “addresses the limiting factors of current blue light with one easy-to-use integrated system,” the webinar narrator states, by displaying white and blue light images side-by-side simultaneously on the surgeon’s monitor and by providing a device that consolidates the surgical light source, video camera and data recording technology in an implement that is adaptable to almost any scope on the market. “Leading urologists have told us that the ability to see both images at the same time will allow them to efficiently eliminate more cancer cells,” the narrator states. “No matter which standard scopes a hospital owns today, they cannot use blue light with them. Imagin solves this problem with a system-agnostic camera head that will work with almost any standard cystoscope that a hospital already owns.” The company’s initial i/Blue Imaging product is purposed for bladder cancer surgeries, but the company intends to expand its technology for multiple endoscopic medical procedures in the future, including laparoscopic, colorectal and thoracic procedures that use a variety of contrast dye agents and illumination sources. Last month, the company closed the first $750,000 tranche of a proposed investor offering of up to $3 million in aggregate principal (https://ibn.fm/HhVRg) in convertible notes. The notes can be converted to units that will be made up of one post-consolidated common share, a one-half common share purchase warrant exercisable at $0.50 USD and a one-half common share purchase warrant exercisable at $0.60 USD. The notes will accrue 10 percent interest annually, payable semi-annually in arrears; and will mature 18 months following the date of issue, according to the company (https://ibn.fm/LCAFo). For more information, visit the company’s website at www.ImaginMedical.com. NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Precision medicine is emerging approach to disease prevention, treatment that incorporates individual’s distinctive characteristics.
• New approach allows doctors, researchers to predict more accurately which treatments may work better.
• Helomics’ database, largest of its kind, is comprised of ovarian, head and neck, colon and pancreas tumors.

Science has discovered that thumbprints and DNA aren’t the only biological elements that make individuals unique. In fact, ears, eyes, tongues and even the way a person walks is distinctive, unlike anybody else in the world (https://ibn.fm/SJX27). Moreover, the things that make people different from each other don’t stop at physical characteristics. Predictive Oncology (NASDAQ: POAI) is building a business around precision medicine, an emerging approach to disease prevention and treatment that identifies the variability in genes, environment and lifestyle for each individual, and then uses that information to provide individualized treatments designed to ultimately improve patient outcomes (https://ibn.fm/Va9HX). “This new approach will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people,” explains a MedLinePlus article. “It is in contrast to a one-size-fits-all approach, in which disease treatment and prevention strategies are developed for the average person, with less consideration for the differences between individuals.” POAI realizes that “just genomics” is not enough to deliver personalized therapeutic options. The company believes that a multi-omic approach to disease, or one that gathers data from multiple levels such as genome, epigenome, transcriptome, proteome and metabolome, offers a much greater chance of success. With that in mind, Predictive Oncology is addressing cancer, specifically ovarian cancer, by leveraging the synergies of two of its wholly owned subsidiaries — Helomics and TumorGenesis — to bring precision medicine to the space. One of POAI’s highest priorities is building multi-omic predictive models of tumor drug response and outcome. The company accomplishes this through its subsidiary Helomics and by using its proprietary TumorSpace knowledge base of 150,000 tumor drug response profiles gathered from more than 15 years of clinical testing. “We have developed a unique technology that combines our clinically validated primary tumor cell assay and drug response data . . . together with proven artificial intelligence (AI) to allow us to test potential drugs against patient tumor cells, much earlier in the drug discovery process,” the company explains (https://ibn.fm/GRRXb). “We believe this patient-centric approach will significantly improve the success of translating compounds into the clinic, saving time, cost, and most importantly getting therapies to patients more quickly.” Helomics’ database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. The company’s CLIA-certified lab provides testing that assists oncologists in identifying personalized patient treatment options. TumorGenesis is developing a new approach to growing tumors in the laboratory without the use of rats or mice. This exclusive methodology “fools” the tumor into thinking it is still in the body; therefore, it reacts as it naturally would, increasing the accuracy of the biomarker. These biomarkers are then used in TumorGenesis’ Oncology Capture Technology platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples. The process provides critical information that can be used to develop patient-specific treatment options. For more information on Predictive Oncology, visit the company’s website at www.Predictive-Oncology.com. NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• HempFusion Wellness, Inc. is developing nutritional products (currently 46 on retail store shelves) that promote overall health and wellness in a variety of ways including skin care, pain relief and gut support
• The company’s products are distributed to about 4,000 retailers in all 50 states as well as some international outlets, including major food and drug retailers and big box stores mostly not available to other CBD companies
• HempFusion has filed a preliminary prospectus for a planned initial public offering (“IPO”) on Canada’s most senior stock exchange, the TSX
• Market watchers expect the CBD industry to expand to $12.4 billion by 2023 and current trends point to the expansion of subsectors such as the infused beverage industry, which is expected to reach $2.8 billion by 2025

It’s easy to sympathize with players in the hemp / CBD market who felt a sense of whiplash in 2020 as a once-hot sector suddenly found itself facing a wolf at the exchange door. A booming supply of hemp from farmers looking for a sudden new cash crop after the 2018 farm bill legalized hemp cultivation as an agricultural product led to an extreme oversupply (https://ibn.fm/iutHs), followed by a drop in demand as the global COVID pandemic led many wellness product fans to turn away from CBD in favor of specialized immunity-enhancing supplements (https://ibn.fm/0lqAn). Even so, analysts continue to anticipate a market resurgence as the supply and demand actors figure out how to balance product delivery. The (thus-far-contested) victory of President-elect Joe Biden also is expected to open a new wave of optimism, given Biden’s plans to decriminalize marijuana, a sibling to hemp, in contrast to the current president’s policies, as well as the decisions by five states to newly legalize recreational marijuana use and/or medical marijuana (https://ibn.fm/7WYSJ). Researchers at market analysis firm Brightfield Group cut their estimates for CBD (cannabidiol) almost in half from $23 billion in 2023 to $12.4 billion, but that still amounts to a healthy-sized product pipeline, and Brightfield sees the market continuing to grow to $16.8 billion by 2025 (https://ibn.fm/MotmC). Grand View Research analysts predict the CBD-infused beverage subsector could expand to $2.8 billion by 2025 (https://ibn.fm/TRafg), and New York may be leading the charge with efforts to refine its regulations to permit such beverages (https://ibn.fm/gbp09). Expectations for a hemp market revival underlie the optimism of Denver-based HempFusion Wellness, which has developed 46 CBD products that are currently on retail shelves and is now pursuing a proposed initial public offering of common shares and a listing on the Toronto Stock Exchange, which makes the private company the first U.S.-based cannabidiol (“CBD”) business to apply to list on the TSX senior board (https://ibn.fm/ex0g1). CBD has gained an exponential growth in users during recent years despite disagreements over its legal status. In 2018, about $620 million in CBD products were sold to consumers. In 2019, before the pandemic struck world economies, CBD sales jumped 706 percent (year-over-year) to $5 billion (https://ibn.fm/w2Q5s). Likewise, product sales for pet-friendly CBD rose from $8 million in 2017 to $32 million in 2018, marking a 300 percent expansion. HempFusion’s investment in meeting regulatory standards while the market has been in its infancy has opened doors to outlets in major food and drug retailers and big box stores that are not available to other CBD companies, as well as through physician pipelines. The company’s leading offerings include HempFusion-owned Biome Labs, HF Labs and Probulin. Its line of topical products includes creams and balms that specifically target acne, anti-aging, sports pain relief, eczema relief and wound care, and Probulin Probiotics is considered to be one of the fastest growing probiotics brands in the United States, according to SPINs reported data (https://ibn.fm/Mlre8). HempFusion products are distributed to about 4,000 retailers in all 50 states, and to some international outlets as well. For more information, visit the company’s website at www.HempFusion.com/Corporate-Information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/HempFusion

• Company plans to first uplist to TSX from its current TSX.V listing. Uplisting benefits include enhanced visibility and potentially increased access to capital
• If TSX uplisting is successful, Loop has plans for a possible dual listing by filing with the SEC and NASDAQ
• Company anticipates significant growth to continue in 2021, following an increase in demand for its products and services, resulting in higher sales, customer acquisitions, partnerships, technology stack and deployments
• New proprietary technology, Uklipz, is expected to launch in January 2021, joining the company’s current lineup of IoT and AI products

Loop Insights (TSX.V: MTRX) (OTCQB: RACMF), an innovative technology company leveraging Internet of Things (“IoT”) technologies to deliver contact solutions, has announced its intention to begin the uplisting process to major North American Stock Exchanges. The uplisting plan was approved by the Board of Directors and comes at a time of extraordinary growth for the company in terms of sales, customer acquisitions, partnerships, technology stack and deployments (https://ibn.fm/ZjIlP). The company expects demand for its AI data applications and product services to continue throughout 2021, as a result of the digital transformation driven by COVID-19, spurring significant growth and market opportunities. “As a result of our immutable relevancy, high demand for Loop’s products, pipeline growth, and ability to easily scale into a global marketplace that is in full press digital transformation, we expect a continued accelerated pace that now warrants an uplist and dual list strategy that will attract institutional investors commensurate with our anticipated profile in 2021 and far beyond,” CEO Rob Anson, said about the uplisting announcement. Loop’s proposed plan for uplisting involves applying to have common shares uplisted to the Toronto Stock Exchange (“TSX”) as a technology company from the current TSX Venture Exchange (“TSX.V”) listing. Certain conditions must be met for the TSX uplisting, as well as approval of the TSX listing application. If the TSX uplisting is successful, as soon as practical, Loop intends to begin the process of filing a Form F-1 Registration Statement with the Securities and Exchange Commission of the United States (“SEC”), enabling it to apply to be listed on the NASDAQ. The Board and legal advisors believe that a NASDAQ listing will be better served from a TSX company instead of TSX.V. Unfortunately, there is no guarantee that the SEC or the NASDAQ applications will be approved. Loop may not continue with the uplisting to TSX or NASDAQ should the market conditions become unfavorable, they find themselves in additional regulatory or financial burden by being listed, or other conditions that could affect the business operations of the company. Many companies that graduate to the TSX listing come from TSX.V listings (https://ibn.fm/MYjPK). The benefits of uplisting to TSX from TSX.V include:

• Cost Savings – The TSX listing application fee will be waived for eligible TSX.V issuers, but original listings still apply.
• Reduction of Documentation – Some of the issuer information on file with TSX.V can be accessed by TSX, which lowers the number of documents required for submission.
• Waiver of Sponsorship – In some situations, the requirement for sponsorship may be waived for qualified TSX.V issuers.

Additional benefits of listing on TSX may include increased access to capital, greater visibility, enhanced liquidity on world markets and improved M&A opportunities. Since its foundation, Loop Insights’ core goal was to become the first publicly traded, artificial intelligence, data play delivering the ability to connect and provide real-time data applications across in-store, e-commerce and m-commerce channels. The company achieved this goal in 2020, while beginning to commercialize and build a strong pipeline of tier-1 global brands. The company’s innovative technology consists of a line of simple, yet powerful technologies designed to transform industries through the power of IoT technologies and artificial intelligence. The company’s proprietary products include Fobi, SmarTap, Loop Cloud, and Uklipz. Fobi is an IoT device that is designed to integrate with point of sale or customer management infrastructures. SmarTap is a near field communication (“NFC”) device that consumers tap to check into location using the NFC capability of your smartphone. Loop Cloud brings together data points from both Fobi and SmarTap to create a unified database. Uklipz, which is expected to launch in January 2021, offers a next-generation platform that enables consumers to create video reviews that can be purchased, analyzed, and leveraged by brands to drive engagement and sales. In addition, the company has deployed its technology to create a venue management platform designed specifically for COVID-19 tracing. This complete, end-to-end management platform enables venues and event hosts to manage attendees and instantly trace and notify potential at-risk visitors. For more information, visit the company’s website at www.LoopInsights.ai NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at https://ibn.fm/RACMF

• Rritual Superfoods, Inc., is a budding new superfood developer aiming to improve people’s overall wellness with purposefully designed elixirs pairing acclaimed mushroom varieties with adaptogenic herbs
• The company was organized earlier this year and has launched three initial product varieties using the Chaga, Reishi and Lion’s Mane mushrooms in tandem with adaptogenic roots plus herbal spices and natural whole foods
• Rritual’s products are designed to help users combat stress, strengthen their immune systems and enhance their mental clarity
• The nascent functional mushroom market is expected to grow with a CAGR of 8.04 percent between 2019 and 2024, according to Mordor Intelligence

For millennia, eastern cultures depended on traditional health practices that have gained some legendary status despite the prevalence of “modern” medicine’s drugs, devices and practices in Asian countries now. English missionaries transported their science to the orient in the early nineteenth century, but even though such health efforts are now well established throughout the continent traditional Chinese medicine (“TCM”) remains a popular lifestyle choice and is gaining a growing influence in Western cultures as well (https://ibn.fm/zwuFj). Therapeutics innovator Rritual Superfoods is drawing on the collective wisdom of the ancients to provide natural wellness alternatives to modern remedies for a variety of conditions. Integrative medicine specialist Dr Andrew Weil recently commented in a news report that mushrooms have been used in Asia to improve health, maintain vitality, preserve a youthful appearance and to counter the adverse health effects of chronic stress for generations (https://ibn.fm/a7mer). Rritual Superfoods combines select varieties of the fungi with herbs renowned for similar wellness-enhancing properties to create shelf-ready elixirs and powders that consumers can adapt to their needs. The three elixir varieties that make up the company’s initial product launch are available in 14-stick packs and in 250-gram tubs, plus a 14-day variety pack that includes all three formulations. Rritual was established earlier this year and is building its brand beginning with the Chaga mushroom renowned as a means of strengthening the immune system, the Lion’s Mane mushroom touted as supporting mental clarity and brain health, and the Reishi mushroom to boost the body’s ability to fight anxiety. Chaga, the “king of mushrooms,” is paired with Eleuthero root, which is also known as Siberian ginseng (not to be confused with standard ginseng), an energy-enhancing adaptogenic herb used for centuries in TCM and other Asian herbal remedies. Lion’s Mane is partnered with Rhodiola root, and Reishi, otherwise known as “the mushroom of immortality” in TCM, is paired with Ashwagandha root. The company relies on herbal spices like cinnamon and ginger as well as whole foods like coconut powder and whole fruit powders to cement a delicious taste using very purposeful, organic ingredients. Rritual has its own mushroom adaptogen news app at the Apple Store and on Google Play to showcase its authority in related product information. Cannabis clinician Dr. Mike Hart became the company president during the summer, guiding Rritual to organic certification from the U.S. Department of Agriculture (“USDA”), which the company announced it had achieved in November (https://ibn.fm/rSGen). “Receiving USDA Organic Certification provides trusted, third-party validation of the quality of Rritual’s products,” CEO David Kerbel stated at the time. “We have a premium lineup that features powerful ingredients and with the addition of a Certified Organic seal our consumers can be confident they are making healthy, informed decisions about what they are putting in their body when they purchase Rritual.” For more information, visit the company’s website at https://investors.wearerritual.com. “Mental Fitness is a Daily Ritual” NOTE TO INVESTORS: The latest news and updates relating to Rritual are available in the company’s newsroom at http://ibn.fm/Rritual

• Precision oncology leverages the profile of genetic mutations in patients for the purpose of delivering precision drug-based cancer therapy
• Precision oncology industry forecast to be worth 99.72 billion by 2027 according to recent report
• POAI applies AI to proprietary data trove, aiding oncologists in personalizing cancer therapies in addition to collaborating with pharmaceutical companies for drug discovery

Precision oncology is driven by the profile of genetic mutations in tumors that give practitioners required information to target therapies based off the specific mutations in the patient’s tumor. According to a recent research report, the industry is predicted to be worth 99.72 billion by 2027 as a result of synergistic efforts between big data healthcare organizations and pharmaceutical companies (https://ibn.fm/ss0Ez).  Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company that focuses on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery for cancer, is positioned to play a critical role in industry growth through its integration of AI technology into oncologists’ clinical decision-making processes, paving the way for better health outcomes. Recent advances in cancer care have been closely associated with genomic medicine, fueled by research confirming correlations between specific genetic mutations and several tumors and tumor types. These advances hold promise for oncologists who use genomic testing to look for genetic mutations in patients when determining the most appropriate treatment options for their patients. POAI is focused on the use of data and artificial intelligence to develop personalized cancer therapies through its trove of valuable assets, including a database of clinically validated historical and outcome data from patient tumors, an in-house Clinical Laboratory Improvement Amendments (“CLIA”)-certified lab, a “smart” patient-derived tumor profiling platform, an in-house bioinformatics artificial intelligence platform, and a proprietary approach to growing tumors in the lab to rapidly develop patient-specific treatment options The growth of precision medicine in cancer therapeutics has been driven in recent years by analysis of patients and tumors mutations and their responses to pharmaceutical treatments. The process is both resource and time-sensitive, often requiring years of clinical evaluation and observation to produce data that determines treatment efficacy tied to a particular therapy POAI is ahead of the curve through its vast collection of tumors, their related data, the company’s ability to access associated outcome data, and the application of AI to more than 150,000 tumors in its database. Along with assisting oncologists in prescribing precision cancer treatments, POAI’s data-driven approach propels research forward for the development of drug therapies through the company’s collaborations with pharmaceutical companies. POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow. For more information on Predictive Oncology, visit the company’s website at www.Predictive-Oncology.com. NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• “Energy Fuels will always, first and foremost, be a uranium producer,” says CEO
• Company is playing it smart with financial stability, scalable production and additional revenue streams that utilize existing facilities
• Additional revenue streams include rare earth elements, vanadium, uranium recycling, and land clean-up

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading U.S.-based uranium mining company that supplies major nuclear utilities and is making huge moves into the rare earth elements (“REE”) space, is debt free and boasts diverse cash-flow-generating opportunities. In addition to uranium and REEs, the company produces vanadium, recycles uranium-bearing products and participates in land clean-up initiatives. “Energy Fuels will always, first and foremost, be a uranium producer,” said Energy Fuels president and CEO Mark S. Chalmers (https://ibn.fm/TMadM). “We have been the number one uranium miner in the U.S. since 2017, a position we intend to keep for many years to come. However, when other complementary business opportunities arise with the potential to create significant cash flow utilizing our existing facilities and workforce, we will always take a hard look at them with an eye toward building shareholder value.” An exciting development for the company is in rare earth minerals (“REEs”). By taking advantage of existing infrastructure and proven technologies, Energy Fuels has the potential to be one of the lowest-cost REE producers in the Western world.  The company recently produced a rare earth carbonate on a pilot scale from natural monazite ore at its 100% owned White Mesa Mill, located near Blanding, Utah. Energy Fuels recently announced that it secured a long-term supply of high-grade REE and uranium-bearing monazite from The Chemours Company. The company expects to be in commercial production of a mixed RE carbonate in Q1 2021. Upon successful ramp-up, Energy Fuels will be producing an REE product at a more advanced stage than any other U.S. company. This REE concentrate was produced using infrastructure and technologies already available and in operation at the mill. The process recovered high concentrations of REEs from the monazite sands, in addition to the contained uranium. In addition, uranium is seeing an increase in demand as countries turn toward carbon-free energy options. Nuclear energy, fueled by uranium, provides a reliable and affordable option. This clean solution gives off zero carbon emissions or air pollution. In 2019 the U.S. nuclear industry generated more than 809 billion kilowatt-hours of electricity, enough to power more than 66 million homes. Yet, in 2019 the U.S. produced almost no uranium, making the nation almost completely dependent on imports (https://ibn.fm/QVTY8). As a result, there is bipartisan support for the U.S. government to create a strategic U.S. uranium reserve, similar to the strategic petroleum reserve, meant to revive and expand the production of domestic uranium. For the first time since 1972, the Democrat platform supports nuclear, and the industry is experiencing bipartisan support. Even with the promise of growth in the REE and uranium industries, Energy Fuels is playing it smart by creating financial stability, scalable production and additional revenue streams that utilize existing facilities. The company became debt free in October 2020, and Energy Fuels can quickly increase uranium production from three different uranium production facilities: one currently in operation and two on operational standby. The company also owns several additional licensed and constructed mines to feed those production facilities; additional revenue streams include vanadium, uranium recycling and land clean-up. Finally, Energy Fuels is helping in the clean-up of Cold War-era, government uranium sites. The White Mesa Mill is the only facility in the country that can recycle clean-up material into salable uranium. The company is also currently supporting the clean-up of a private mine in New Mexico and a pilot-scale project on Navajo Nation, which has been delayed due to COVID-19. For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• Study published in “JAMA Psychiatry” reveals significant benefits of psilocybin for patients with major depression
• Most participants reported improvements; half experienced remission after only four weeks
• As an early entrant in the field, Cybin looks well placed to capitalize on growing traction that psychedelics gain as potential treatment of mental health conditions

Only two doses of psilocybin accompanied with psychotherapy may lead to significant reductions in depressive symptoms in adults with major depression, according to recent research conducted by Johns Hopkins Medicine and published in “JAMA Psychiatry” (https://ibn.fm/AM1Ww). As a leading life sciences company focused on psychedelic drug development, Cybin (NEO: CYBN) is set to capitalize on the growing body of research indicating the significant role this compound could play in alleviating symptoms of major depression. This most recent study came after Johns Hopkins Medicine scientists first found in 2016 that psilocybin treatment, coupled with psychological support, considerably eased existential anxiety and depression in people with a life-threatening cancer diagnosis. The previous research sparked interest in further exploration of the potential of psilocybin to treat major mental health disorders, which lead to conclusions that this compound could potentially help a much wider population. As a result, the world-renowned research center continued to investigate psilocybin applications in this field. Part of these scientific efforts are included in the latest study, which covered 24 participants with a documented history of persisting symptoms of depression over approximately two years before enrolling in the study. For the study, participants were required to taper off any antidepressants under medical supervision to ensure the safety of this experimental treatment. All participants were given two doses of psilocybin two weeks apart, but to disentangle the impact of psilocybin, researchers split the participants into two groups: one group received the psilocybin treatment immediately after enrollment, and the other group received the same treatment after an eight-week delay. To measure this experimental treatment’s impact, participants were assessed on the GRID-Hamilton Depression Rating Scale three times: at the beginning of the study and one week and four weeks after the treatment was completed. This scale is a standard depression assessment tool used to evaluate the severity of depression in patients suffering from this widespread mental health condition. The findings revealed that most participants demonstrated a substantial decrease in their symptoms, and almost half were in remission from depression at follow-up. For example, one week and four weeks after treatment, the average depression scale score dropped from an initial 23 to 8. Four weeks after the treatment, 54% of participants were considered in remission. Participants in the delayed group did not show decreases in their symptoms before receiving the psilocybin treatment. “The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” reported Alan Davis, PhD., adjunct assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. These results confirm that Cybin, a company committed to becoming one of the first life sciences companies to develop a fully approved psilocybin product targeting depression, is on the right track. CYBN is intent on providing solutions to the more than 17 million people in the United States and 300 million people worldwide who suffer from depression. The company has been focusing its efforts on psychedelic drug development and unique delivery mechanisms and protocols that target psychiatric and neurological conditions. Long the subject of skepticism and stigma, psilocybin has recently become a focus for a number of academic institutions and companies hoping to capitalize on the momentum this compound is building both in scientific and commercial space. Cybin Inc. is leading the charge. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Tech start-up pioneer Knightscope is becoming known for its artificial intelligence-enhanced robot sentries that are capable of performing many security functions while reducing the risk of human error and human exposure to danger
• The company’s production models range from stationary, indoor machines to mobile, outdoor machines equipped with a range of technological features including 360-degree eye-level HD streaming video, face and license plate recognition, and infrared thermal detection
• These automated security sentries can provide crime deterrence in a non-violent, non-threatening manner as agencies adapt to community concerns about law enforcement’s evolving roles
• While Knightscope is not listed on a public exchange, its shares are available for purchase through its Reg A+ offering and the company continues working toward a public stock listing, according to a recent blog post

In 1968, science fiction author Phillip K. Dick wrote a novel about a society 50 years in the future in which police used artificial intelligence, video calls, voice-activated personal assistants, and flying cars. Now, a year beyond the 2019 society of “Do Androids Dream of Electric Sheep?” and its film counterpart “Blade Runner,” many of those technologies have found a real expression in modern-day police work. Visionaries are anticipating further technological transformations as rapidly changing innovations in communication and data storage define our daily life, as noted in a pre-pandemic Deloitte analysis of the security industry (https://ibn.fm/kxUFa). Autonomous security robot developer Knightscope is an example of ways private industry is working with government-established law enforcement agencies to make a quantum leap in police responsiveness to emerging tech trends. The company’s roving mechanical sentinels employ 360-degree eye-level HD streaming video, people detection and facial recognition features, automatic license plate recognition, thermal anomaly detection, and automatic signal detection to help prevent crime, record evidence of potential crime, and make that evidence as well as other data reliably available to human analysts for justice system follow up. Indeed, the dialogue might as well be more about community protection than crime interdiction — Knightscope’s sentinels have demonstrated their usefulness more broadly by using the thermal camera to recognize a heat anomaly within a client business, for example, alerting emergency responders to a developing fire hazard before an out-of-control blaze could do significant damage (https://ibn.fm/NwcoV). This emphasis on community safety and a cost-competitive solutions approach to marketing the robotic security models have gained Knightscope the backing of four major corporations and more than 17,000 investors, many of whom are “chief security officers of major corporations … NYPD detectives, (representatives of the) FBI, CIA, (and) DHS,” according to CEO William Santana Li (https://ibn.fm/2tcrD). Although the company is privately held, Knightscope continues working toward going public. A recent blog entry noted the company is indeed “pursuing a successful listing and (continuing) to focus on that process” (https://ibn.fm/uybmn). In the meantime, interested members of the public can invest in Knightscope through the company’s Reg A+ offering. While Knightscope’s technology is far from the police cyborg action envisioned by “Robocop,” it is part of an adaptive effort that is responding to recent societal concerns about police-related violence that have ironically become more pronounced amid the adoption of technology designed to instill greater confidence in law enforcement activities. Barely a decade has passed since “Taser Cams” and police car dash cams made a splash (https://ibn.fm/G4f0G) that gave rise to body-mounted cameras worn on officers’ uniforms (https://ibn.fm/fWYwh) for supporting officers’ reports on their activities. The University of Oregon’s recent announcement that it will convert many of its armed police officer job openings to unarmed “community service” patrol officer positions that are designed more to create a crime-discouraging presence and an informational front-line with the support of a decreased number of armed police personnel backups is emblematic of agencies’ efforts to adapt to their communities’ concerns (https://ibn.fm/KoY7n). Factor in the economic ravages of this year’s pandemic and uncertainty about when (or how) life will return to “normal,” and some analysts foresee a pending “great reset” in which vehicular automation, prison and jail population reductions and stay-at-home workforces drive a system in which many core law enforcement activities are regionalized, with community agencies focusing on community service, family counseling and code enforcement (https://ibn.fm/BYaMP). However things develop, Knightscope’s artificial intelligence-enhanced security models have the tools to adapt to conditions and support agencies’ emerging needs. For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• HempFusion is one of 12 companies working on a study to address FDA comments about CBD and human interaction, studying the cannabinoid’s effects on the human liver
• The company could become publicly traded on the Toronto Stock Exchange as early as the week starting December 14, 2020
• By 2025, the global CBD market is estimated to reach $23.6 billion
• HempFusion plans to extend product offering to include beverages, edibles, and pet products, which has become a growing segment in the CBD industry

A leader in the health and wellness cannabidiol industry, HempFusion Wellness is raising the bar for CBD products everywhere through an unwavering commitment to quality and safety of products, effectively standing out from other companies in the industry that sell sub-standard and ineffectual products. To prove its commitment to the quality and purity of its offering, HempFusion became U.S. Hemp Authority Certified and is also on board for the U.S. Hemp Round Table, a coalition of leading companies committed to bringing safe hemp and CBD Products to the market. Further demonstrating its dedication, the company was one of 12 CBD organizations conducting a study designed to address Food and Drug Administration concerns regarding CBD products and human safety. Throughout the study, HempFusion and the other selected companies conducted human trials to determine if the daily used of CBD isolate or CBD derived from hemp has any impact on the human liver. Results of the groundbreaking study, organized by ValidCare, will be shared with the FDA and published in a peer-reviewed journal in early 2021. Driven by this commitment to quality and compliance, HempFusion provides innovative and diversified proprietary formulations utilizing the power of whole-food hemp nutrition. The company’s portfolio includes 46 products currently on shelves, distributed to approximately 4,000 retailers nationwide and select international locations, with a pipeline of 26,000 stores. The products are distributed through the company’s family of brands: Probulin Probiotics, Biome Research and HF Labs. The company’s goal is to create a portfolio that sets itself apart from other industry companies by adhering to regulatory compliance and human-safety backing. To cement its position on the market and garner investor interest, HempFusion is now taking steps to go public, and on October 22, the company announced that it had already filed a preliminary prospectus in preparation for a public debut. The preliminary prospectus was filed with the applicable securities regulatory authorities for a proposed initial public offering (“IPO”). HempFusion, although Denver-based, plans to list with the Toronto Stock Exchange (“TSX”) using the ticker symbol ‘CBD.U.’ Reports indicate that this could take place as early as the week starting December 14, 2020 (https://ibn.fm/EMeZB). “We are incredibly excited to announce our initial public offering and HempFusion’s intention to list its securities on the Toronto Stock Exchange. To be the first US-based CBD company to apply to list on the TSX is a tremendous honor,” company CEO, President and Co-Founder Dr. Jason Mitchell, N.D., said while discussing the preliminary prospectus and IPO.  “Completion of this proposed initial public offering will accelerate our ability to scale HempFusion’s operations both domestically and internationally, drive accelerated growth within all our distribution channels, and significantly expand our marketing initiatives” (https://ibn.fm/us8zH). The company plans to extend its branded product offerings, both in the U.S. and internationally, offering beverages, edibles, and pet products. This creates new opportunities for growth, as the global CBD market, as well as the pet CBD sector are growing exponentially. The global market for CBD was valued at $4.6 billion in 2018 and this year, it is estimated to reach $9.3 billion. The market is projected to grow to approximately $23.6 billion by 2025 (https://ibn.fm/aDjcV). In turn, the pet CBD products market is one of the fastest-growing segments in the industry. The market value for 2020 is estimated at $37.4 million and is expected to grow to $399.2 million by 2027 (https://ibn.fm/WIJza). For more information, visit the company’s website at www.HempFusion.com/corporate-information NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/HempFusion